How should we be using biomarkers in trials of disease modification in Parkinson's disease?

Vijiaratnam, Nirosen; Foltynie, Thomas

Vijiaratnam, Nirosen; Foltynie, Thomas.

Affiliation

Vijiaratnam N; Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London WC1N 3BG, UK.
Foltynie T; Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London WC1N 3BG, UK.

Brain ; 146(12): 4845-4869, 2023 12 01.

Article in En | MEDLINE | ID: mdl-37536279

Subject(s)

Cognitive Dysfunction; Parkinson Disease; Humans; Parkinson Disease/metabolism; alpha-Synuclein; Biomarkers/metabolism; Cognitive Dysfunction/complications; Longitudinal Studies

Key words

Parkinson's disease; biomarkers; clinical trials; disease modification

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Parkinson Disease / Cognitive Dysfunction Type of study: Prognostic_studies Limits: Humans Language: En Journal: Brain Year: 2023 Type: Article Affiliation country: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google